CNTB — Connect Biopharma Holdings Income Statement
0.000.00%
Last trade - 00:00- $139.76m
- $84.98m
- $26.03m
Annual income statement for Connect Biopharma Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 20-F | 20-F | 10-K | 10-K |
| Standards: | IFRS | IFRS | IFRS | USG | USG |
| Status: | fx Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 26 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 28.7 | 98.1 | 119 | 69.1 | 48.5 |
| Operating Profit | -28.7 | -98.1 | -119 | -69.1 | -22.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -113 | -202 | -118 | -62 | -15.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -113 | -202 | -118 | -62.1 | -15.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -113 | -202 | -118 | -62.1 | -15.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -113 | -202 | -118 | -62.1 | -15.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.02 | -3.88 | -2.09 | -1.13 | -0.257 |